Curative Biotechnology (Curative Biotechnology) Construction In Progress : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Construction In Progress?

Curative Biotechnology Construction In Progress Historical Data

The historical data trend for Curative Biotechnology's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology Construction In Progress Chart

Curative Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

Curative Biotechnology Quarterly Data
	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Curative Biotechnology Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Curative Biotechnology (Curative Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431

Website

https://www.curativebiotech.com

Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.